Summary
AbbVie Inc. reported its second-quarter and first-half 2014 financial results, showcasing moderate sales growth driven by its flagship product, HUMIRA. Total net sales increased by 5% year-over-year for both the three and six-month periods, reaching $4.9 billion and $9.5 billion, respectively. This growth was primarily attributed to strong performance in HUMIRA, which saw a significant 26% and 22% increase in sales for the respective periods, and contributions from other key products like Synthroid and Creon. Despite overall sales growth, AbbVie experienced a substantial decline in its lipid franchise due to loss of exclusivity, with sales down 82% and 77% in the respective periods. The company also noted a decrease in AndroGel sales due to market contraction. Net earnings showed a slight increase, with diluted EPS at $0.68 and $1.29 for the three and six months ended June 30, 2014, respectively. The company continued to invest heavily in Research and Development, with R&D expenses increasing by 18% and 20% in the respective periods, reflecting its commitment to pipeline advancement. Notably, AbbVie announced a significant subsequent event: a recommended combination with Shire plc, which is expected to create a larger and more diversified biopharmaceutical company.
Financial Highlights
51 data points| Revenue | $4.93B |
| Cost of Revenue | $1.11B |
| Gross Profit | $3.81B |
| SG&A Expenses | $1.45B |
| Operating Expenses | $3.41B |
| Operating Income | $1.51B |
| Interest Expense | $73.00M |
| Net Income | $1.10B |
| EPS (Basic) | $0.69 |
| EPS (Diluted) | $0.68 |
| Shares Outstanding (Basic) | 1.59B |
| Shares Outstanding (Diluted) | 1.61B |
Key Highlights
- 1AbbVie reported a 5% increase in net sales for both the three and six months ended June 30, 2014, reaching $4.9 billion and $9.5 billion respectively.
- 2HUMIRA sales demonstrated robust growth, increasing by 26% and 22% for the three and six-month periods, respectively, driven by strong market performance and new indications.
- 3Lipid franchise sales experienced a significant decline of 82% and 77% due to loss of exclusivity and generic competition.
- 4Research and Development expenses increased by 18% and 20% year-over-year, indicating continued investment in pipeline development.
- 5Diluted Earnings Per Share (EPS) were $0.68 for the three months and $1.29 for the six months ended June 30, 2014.
- 6The company announced a subsequent event involving a recommended combination with Shire plc, aimed at creating a larger, diversified biopharmaceutical entity.
- 7AbbVie generated $2.3 billion in cash flow from operating activities for the first six months of 2014.